logo
Alzheimer's and dementia 'risk increases due to one common sleep issue'

Alzheimer's and dementia 'risk increases due to one common sleep issue'

Daily Mirror20 hours ago
Interrupted sleep can cause damage to the brain's blood vessels, a new study claims.
Broken and disturbed sleep could leave you vulnerable to developing dementia, groundbreaking research has revealed.

Experts from the University of Toronto discovered disrupted sleep can inflict harm on the brain's blood vessels after studying more than 600 elderly participants.

The volunteers wore smartwatch-style devices to monitor their sleep patterns and underwent genetic testing to assess pericyte levels in their brains.

Following their deaths, they donated their brains for scientific examination.
"We found that individuals who had more fragmented sleep, such as sleeping restlessly and waking up a lot at night, had a change in their balance of pericytes - a brain blood vessel cell that plays an important role in regulating brain blood flow and the entry and exit of substances between the blood and the brain," Andrew Lim, principal investigator of the study, said, reports the Express.
Mr Lim added: "This in turn was associated with more rapid decline in cognitive function in the decade leading up to their death."

Addressing sleep disruption could offer a pathway to enhancing brain vascular health, the research concluded.
Mr Lim said: "We know that in some individuals, sleep disruption can precede the onset of cognitive impairment by years, with emerging evidence suggesting a bidirectional link between sleep disruption and Alzheimer's disease."
Nevertheless, until this point, researchers "didn't have sufficient evidence behind the mechanisms underlying these links", he clarified. The research team examined "predominantly older women of European ancestry", so recommended future studies in different populations would be beneficial to establish how widely applicable the findings are.

The NHS recommends a healthy adult typically requires around seven to nine hours of sleep each night.
Nevertheless, factors including age, health and individual circumstances all influence how much sleep is required.
Some people "naturally sleep more than others" according to the NHS.

Infants, children, and teens require more sleep than adults as they are still developing.
If you discover you feel constantly exhausted during the day, you're likely not getting sufficient sleep.
There are currently believed to be nearly one million people across the UK living with dementia, yet more than a third of these individuals lack a formal diagnosis.

Dementia is the term for a collection of symptoms and Alzheimer's is the most prevalent cause - but what exactly are the warning signs?
The initial noticeable indicator is frequently memory difficulties - and someone with Alzheimer's may struggle to recall recent occurrences or absorb new information, the Alzheimer's Society explained.
Someone with the condition might also experience difficulties with focus, planning, and organisation, and may find themselves bewildered about the time of day or their location.
Shifts in temperament - they may become more worried, dejected, or easily irritated - and communication challenges can be typical in someone with the condition.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Vaccine to be given to cancer patients with head and neck tumours
Vaccine to be given to cancer patients with head and neck tumours

The Independent

time29 minutes ago

  • The Independent

Vaccine to be given to cancer patients with head and neck tumours

Patients in England with head and neck cancer will be fast-tracked onto a clinical trial for a potentially transformative new mRNA vaccine. The vaccine uses mRNA technology to train the immune system to fight cancerous cells, specifically targeting proteins found in HPV-associated head and neck cancers. Over 100 patients with advanced forms of the disease will be matched to the AHEAD-MERIT (BNT113) trial, which will run at 15 NHS hospitals over the next year. This trial is the third to be run through the NHS Cancer Vaccine Launch Pad, a partnership between NHS England, the Government, and BioNTech. Health officials and patient advocates have hailed the vaccine as potentially game-changing, offering crucial hope for improved outcomes and reduced recurrence for those with aggressive head and neck cancers.

Shrewsbury and Telford Hospital NHS Trust recruits 167 doctors
Shrewsbury and Telford Hospital NHS Trust recruits 167 doctors

BBC News

time29 minutes ago

  • BBC News

Shrewsbury and Telford Hospital NHS Trust recruits 167 doctors

More than 160 resident doctors have been recruited by Shrewsbury and Telford Hospital NHS Trust (SaTH), it has been 167 clinicians, from all stages of their career, have been inducted, and will now be training and working across disciplines including medicine, surgery and women and children's John Jones, medical director at SaTH,, said: "With them they bring experience and passion to help us to continue to provide excellent care to the communities we serve."The Royal Shrewsbury Hospital (RSH) is undergoing a transformation programme, and this week marked the first anniversary since work started on its four-storey building expansion. The induction programme was delivered by the trust's senior clinicians and other staff, to help the resident doctors, formerly known as junior doctors, become familiar with their new working will now move on to practical and ward-based Jones said: "I am delighted to have welcomed 167 new resident doctors to the trust." Follow BBC Shropshire on BBC Sounds, Facebook, X and Instagram.

Cancer vaccines to be given to patients with deadly head and neck tumours
Cancer vaccines to be given to patients with deadly head and neck tumours

Telegraph

time29 minutes ago

  • Telegraph

Cancer vaccines to be given to patients with deadly head and neck tumours

Cancer vaccines will be given to NHS patients with deadly head and neck tumours. A trial of jabs that could cure people's cancer and prevent it from returning is being expanded to include more than 100 patients with mouth, throat and other head-related cancers, over the next year. The world-first programme has already been trialling personalised cancer vaccines in some 550 patients with either bowel or skin cancers. Tens of thousands of patients will be recruited to trial the various vaccines in development for different forms of the disease over the coming years. The programme, called the NHS Cancer Vaccine Launch Pad, uses a 'match-making' service to partner eligible cancer patients with appropriate trials at nearby hospitals, led by the Southampton Clinical Trials Unit. The cancer vaccines use 'mRNA' technology, first pioneered to create Covid-19 jabs during the pandemic. The vaccine used in this trial, known as AHEAD-MERIT (BNT113-01), will help the immune system recognise and kill cancer cells containing human papillomavirus (HPV) proteins, which are commonly linked to head and neck cancers. Around 11,000 new cases of head and neck cancer are diagnosed in England every year, with a recent University of Sheffield study finding rates had increased by 47 per cent between 2013 and 2020. Aggressive forms of the disease are difficult to treat and have high rates of returning, while fewer than 50 per cent of patients will live for two years after being diagnosed. The vaccine used in the trial is encoded with two proteins that are commonly found in head and neck cancers associated with high-risk types of HPV. It trains the body's immune system to attack and kill the cancer cells. Prof Peter Johnson, NHS England's national clinical director for cancer, said it was a 'potentially transformative vaccine, offering renewed hope of holding the disease at bay'. 'The NHS is always looking for evidence-backed innovations in treatment to improve survival and quality of life for people diagnosed with cancer, and this expansion of our Cancer Vaccine Launch Pad will give hundreds of patients the chance to be part of cutting-edge advances in cancer care,' he said. It will be available to selected patients from 15 NHS hospitals over the next 12 months, NHS England said, which is partnering with German life sciences company BioNTech on the programme. The announcement to expand trials into vaccines using mRNA technology comes after Robert F Kennedy Jr, the US health secretary, announced he would cancel $500 million in funding for mRNA vaccines to tackle viruses that cause diseases such as flu and Covid-19. Kennedy, a vaccine sceptic, said he was pulling the funding over claims that 'mRNA technology poses more risks than benefits for these respiratory viruses', in a move that has been heavily criticised. Karin Smyth MP, the health minister, said the new cancer vaccine trial was a 'massive win' for Britain and 'could be game-changing for patients facing some of the most challenging diagnoses'. 'By getting these trials running in our NHS, we're putting ourselves at the forefront of medical innovation,' she said. Lord Vallance, the science minister and former chief scientific officer for the Government, said: 'Our partnership with BioNTech is delivering for patients right across the country, and I hope to see more ambitious work like this as they continue to invest in research and development and AI as part of their billion-pound backing for the UK over the next 10 years.' Chris Curtis, 67, from Blackpool, was diagnosed with a HPV-related head and neck cancer in 2011 and set up a support charity, The Swallows. He said: 'When I was diagnosed with stage four tongue cancer and two secondary cancers, one each side of the neck, my world just fell apart. 'I then had to go through brutal treatment, including six weeks of radiotherapy, chemotherapy every week, two neck dissections and be fed on a tube for almost three years. I lost 12 stone in weight and was severely physically and mentally unwell. 'With this aggressive cancer you live in fear every day – so anything that could help control the disease or give people peace of mind is ground-breaking. 'It'll allow people to get on with their lives and move forward.' Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said the launch pad was an 'important route to fast-track promising mRNA vaccine technology into clinical trials'. 'Research into personalised cancer treatments is vital. 'There are over 200 different types of cancer and it's unlikely there will ever be a single cure that works for everyone.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store